Holen Sie sich die Stockscreener-App
58.62
1.43%
-0.85
Handel nachbörslich:
58.72
0.10
+0.17%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$59.47
Offen:
$59.79
24-Stunden-Volumen:
8.06M
Relative Volume:
0.61
Marktkapitalisierung:
$119.69B
Einnahmen:
$48.19B
Nettoeinkommen (Verlust:
$7.06B
KGV:
16.95
EPS:
3.4587
Netto-Cashflow:
$12.85B
1W Leistung:
-1.64%
1M Leistung:
-2.51%
6M Leistung:
+33.35%
1J Leistung:
+16.17%
1-Tages-Spanne:
$58.46
$59.80
1-Wochen-Bereich:
$57.65
$59.80
52-Wochen-Spanne:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Firmenname
Bristol Myers Squibb Co
Sektor
Telefon
(609) 252-4621
Adresse
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.62 | 119.69B | 48.19B | 7.06B | 12.85B | 3.4587 |
LLY
Lilly Eli Co
|
939.47 | 839.28B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
238.46 | 574.36B | 94.19B | 26.80B | 19.70B | 11.05 |
ABBV
Abbvie Inc
|
207.94 | 367.80B | 61.16B | 4.19B | 17.82B | 2.3614 |
AZN
Astrazeneca Plc
|
204.03 | 316.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
121.42 | 299.89B | 64.93B | 18.26B | 12.36B | 7.2751 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-12-15 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-12-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-08-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-16 | Hochstufung | Jefferies | Hold → Buy |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-13 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-07-29 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Herabstufung | Societe Generale | Buy → Hold |
| 2024-02-06 | Herabstufung | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-15 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-07-10 | Eingeleitet | SVB Securities | Market Perform |
| 2023-06-28 | Eingeleitet | Daiwa Securities | Outperform |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-01-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Eingeleitet | Credit Suisse | Neutral |
| 2022-10-10 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-09-14 | Herabstufung | Berenberg | Buy → Hold |
| 2022-06-03 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Underweight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-01 | Herabstufung | Argus | Buy → Hold |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Hochstufung | Truist | Hold → Buy |
| 2020-11-16 | Hochstufung | Societe Generale | Hold → Buy |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-11-06 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-07-28 | Eingeleitet | Raymond James | Outperform |
| 2020-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-06 | Fortgesetzt | Citigroup | Buy |
| 2019-12-13 | Hochstufung | Argus | Hold → Buy |
| 2019-11-22 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-08-14 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-05-20 | Herabstufung | Argus | Buy → Hold |
| 2019-05-03 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Fortgesetzt | JP Morgan | Overweight |
| 2019-01-15 | Hochstufung | Societe Generale | Sell → Buy |
| 2018-10-22 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Which Dividend Pharma Stock Should a Value Investor Choose Today? - The Motley Fool
Bartlett & CO. Wealth Management LLC Has $7.26 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
BMY Gains 10% Year to Date: Should You Buy, Sell or Hold the Stock? - TradingView — Track All Markets
Assessing Bristol Myers Squibb (BMY) Valuation After Camzyos Data And T Cell Engager Collaboration News - Yahoo Finance
BMS and Oxford BioTherapeutics join forces in TCE discovery pact - Pharmaceutical Technology
Bristol Myers Squibb stock (US1101221083): Is its oncology pipeline strong enough to unlock new upsi - AD HOC NEWS
Bristol Myers Squibb Cancer Alliance Adds Weight To Valuation Debate - Yahoo Finance
F&V Capital Management, LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Janux secures $35 million milestone payment from Bristol Myers Squibb - MSN
Bristol-Myers Squibb Company (BMY) stock price, news, quote and history - Yahoo Finance Singapore
Bristol-Myers Likely to Get Desired Court in Paxton Plavix Suit - Bloomberg Law News
Oxford BioTherapeutics Partners with Bristol Myers Squibb for Next-Gen T-Cell Therapies - National Today
Bristol-Myers Squibb Earnings Preview: What to Expect - Yahoo Finance
Oxford BioTherapeutics Enters Strategic Collaboration with Bristol Myers Squibb to Discover and Develop Next-Generation T-cell Engagers for Solid Tumours - Yahoo Finance
Cantor Fitzgerald Lifts Bristol Myers (BMY) Price Target but Flags Weak Q1 Catalyst - Insider Monkey
MFS Blended Research Core Equity Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts - Yahoo Finance
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
MapLight's Psychosis Drug Could Deliver Billion-Dollar Upside, Says Analyst - Benzinga
Bristol-Myers Squibb: Vestmo Stock of the Week - Barron's
Cantor Fitzgerald raises Bristol-Myers Squibb stock price target to $54 - Investing.com
Guggenheim reiterates Bristol-Myers Squibb stock rating at Buy - Investing.com
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead to buy Germany's Tubulis for up to $5 billion to boost cancer pipeline - Reuters
Bristol-Myers Squibb Company (BRM.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
BMY Stock Price, Quote & Chart | BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - ChartMill
Bristol-Myers Squibb Company (BMY) latest stock news and headlines - Yahoo Finance UK
Bristol-Myers Squibb Company (BMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Scotiabank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $60 - 富途牛牛
Pleural Diseases Market Set to Boom Rapidly by 2033 |Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc - openpr.com
Nathan Pennell: "Global and Local" Model Takes Focus During BMS Japan Visit - Oncodaily
Case-By-Case Guide As Justices Eye Landmark Pharma Law - Law360
Trust Co. of Toledo NA OH Sells 55,523 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Element Squared LLC Acquires Shares of 48,420 Bristol Myers Squibb Company $BMY - MarketBeat
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock - Investing.com Australia
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance UK
BRISTOL-MYERS SQUIBB CO (BMYS.VI) Q1 FY2025 earnings call transcript - Yahoo Finance
Growth and Income Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term - Yahoo Finance
BRISTOL-MYERS SQUIBB CO (BMYS.VI) Q2 FY2025 earnings call transcript - Yahoo Finance
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co (BMY) Shares Down 3.58% on Apr 2 - GuruFocus
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review - Ad Age
Bristol Myers Squibb Cancer Pact And Equity Push Raise Valuation Questions - simplywall.st
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.58% on Apr 2: What Signal Does It Send? - TradingKey
Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos - Insider Monkey
Ritter Alpha, LP's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tema Etfs LLC Has $6.89 Million Holdings in Bristol Myers Squibb Company $BMY - marketbeat.com
20,914 Shares in Bristol Myers Squibb Company $BMY Acquired by J. Safra Sarasin Holding AG - MarketBeat
Finanzdaten der Bristol Myers Squibb Co-Aktie (BMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):